Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic

Executive Summary

The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.

You may also be interested in...



Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast

Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between. 

ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma

Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.

Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue

Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC100484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel